Safety and efficacy of BIC/FIC/TAF in older PLHIV: impact on bone density, renal function, and lipid profiles in a real-world Chinese cohort Authors: Chengyu Gao, Yi Ding, Jialu Li, Yining Zhao, Qinlan Li, Ying Liu, Hongyuan Liang, Liang Ni, Fang Wang, Sa Wang, Di Yang, Guiju Gao, Jiang Xiao, Hongxin Zhao Published: 2025 ABSTRACT BackgroundThis study aimed to elucidate the efficacy and safety of treatment using a fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in older patients with HIV in the real world.MethodsA retrospective study was conducted at our hospital between April 2023 and April 2024, and the efficacy and safety of treatment with fixed-dose BIC/FTC/TAF were assessed in 314 patients aged > 50 years living with HIV, including 35 antiretroviral therapy (ART)-naïve patients and 279 ART-experienced patients.ResultsFixed-dose BIC/FTC/TAF displayed good efficacy among older patients, even in five patients with the M184V mutation site. At the 48-week follow-up, the absolute change of bone mineral density (BMD) was compared with baseline values, with results as follows: 0.8876 ± 0.1193 vs. 0.9321 ± 0.1071 g/cm2 in L1 (p = 0.030), 0.9260 ± 0.1327 vs. 0.9758 ± 0.1208 g/cm2 in L2 (p = 0.029), 0.9559 ± 0.1386 vs. 1.0139 ± 0.1355 g/cm2 in L3 (p = 0.018), and 0.9411 ± 0.1486 vs. 1.0250 ± 0.1709 g/cm2 in L4 (p = 0.003). The BMD values in the left or right hip joint (neck, trochanter, and inside) and renal biomarkers tended to improve. Significantly increased serum creatinine and reduced eGFR levels were also observed (p < 0.001). Changes in lipid panel values from baseline were as follows: 1.86 ± 1.21 mmol/L vs 1.66 ± 1.00 mmol/L for triglycerides (TGs) (p = 0.013) and 1.11 ± 0.30 mmol/L vs 1.15 ± 0.32 mmol/L for high-density lipoprotein (p = 0.018).ConclusionsBIC/FTC/TAF presented optimal antiretroviral efficacy, including in patients with the M184V mutation site, and significantly improved outcomes in BMD in the lumbar spine and serum TG levels, while outcomes in the left or right hip joint, renal biomarkers, and other lipid panels presented improved trends after 48 weeks of treatment and follow-up in this real-world study.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12050-7. Introduction In China, the number of people aged > 60 years living with HIV has grown rapidly, accounting for 25% of all people living with HIV in China in a new report in 2023 [1], indicating that older adults are facing crucial challenges in AIDS prevention and control. With the advent of antiretroviral therapy (ART), potent antiretroviral regimens have increased survival and prolonged lifespan, resulting in more older patients living with HIV in China, which makes such patients more important for physicians. HIV infection impacts ageing, which may manifest as accelerated age-related changes; advanced age in turn impacts the progression of HIV-associated diseases [2]. Despite potent ART, residual inflammation and biomarkers of immune activation have increased in older patients with HIV compared with in younger patients, contributing to the development of age-associated comorbidities, including metabolic syndrome [3], cardiovascular and cerebrovascular diseases [4], osteopenia/osteoporosis [5], neurocognitive disorders [6] and even malignancies [7]. Reportedly, more older patients suffer from one or more complications or comorbidities, requiring more non-ART medications, and are more likely to experience drug-drug interactions (DDIs), suggesting that ART should be closely monitored for safety and efficacy among these patients [8]. The current guidelines for the diagnosis and treatment of HIV/AIDS in China [9] recommend two nucleoside reverse transcriptase inhibitors combined with an integrase strand transfer inhibitor (INSTI) as the first-line antiretroviral regimen. The fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) is the most common INSTI-containing regimen, which is well tolerated, with few drug-related adverse effects and potent antiretroviral ability. A phase 3b, open-label trial (NCT03405935, 2018–01-23) has demonstrated that at 24, 48 [10], and 96 weeks [11], switching to BIC/FTC/TAF potently suppressed viral load and was an effective long-term choice, with favorable safety and tolerance among patients aged > 65 years. Despite guideline-recommended administration, real-world data on the efficacy, tolerance, and safety of BIC/FTC/TAF treatment in elderly patients living with HIV in China are lacking. This study aimed to elucidate the efficacy and safety of treatment with a fixed-dose combination of BIC/FTC/TAF in elderly patients living with HIV in China. Methods Ethical consideration The retrospective study was conducted at Beijing Ditan Hospital, and the medical ethics committee approved the study protocol and waived the requirement for informed consent due to the anonymous use of retrospective clinical data. Study subjects A retrospective study was conducted, and eligible ART-naive patients were: 1) age > 50 years, 2) ART-naive and initiating ART with fixed-dose BIC/FTC/TAF, and 3) followed up for 48 weeks after BIC/FTC/TAF initiation. Eligible ART-experienced patients were: 1) age > 50 years, 2) previous ART switched to BIC/FTC/TAF, and 3) followed up for 48 week after BIC/FTC/TAF initiation. The exclusion criteria were as follows: 1) age < 50 years, 2) follow-up period < 48 weeks, 3) presence of resistance mutations against TAF and/or BIC. A normal control group including 20 ordinary individuals, and eligible normal control individuals were: 1) age > 50 years, 2) without HIV infection, and 3) hepatic and renal functions are within normal range. Definition Virologic suppression was defined as a confirmed HIV viral load below the lower limits of detection (LLOD) after 24 weeks of ART administration, whereas virologic failure was defined as the inability to maintain suppression of viral replication and viral load > 200 copies/mL. Low-level viremia (LLV) was defined as a viral load ranging from 50 to 200 copies/mL after 24 weeks of treatment. Biochemical tests, including hepatic and renal functions, renal biomarkers, and lipid panels, were conducted periodically, and liver injury was diagnosed based on criteria outlined in “Case definition and phenotype standardization in drug-induced liver injury,” [12] renal dysfunctions was confirmed based on chronic renal dysfunction guidelines [13], and hyperlipidemia was diagnosed based on established diagnostic guidelines [14]. Procedures The participants, including both ART-naive and -experienced, continuously received an oral fixed dose of BIC/FTC/TAF (50/200/25 mg; Biktarvy, Gilead Sciences, Inc. CA, USA) once daily. Laboratory tests, including routine blood and urine tests, hepatic function (alanine aminotransferase [ALT], aspartate aminotransferase [AST], total-value bilirubin [T-BIL], and direct bilirubin [D-BIL] levels), renal function (serum creatinine and estimated glomerular filtration rate [eGFR]), renal biomarkers (quantitative urine albumin, ɑ1-microglobulin, β2-microglobulin, microalbuminuria, and cystatin), serum lipid panel (triglycerides [TG], total cholesterol [TC], low-density lipoprotein [LDL] and high-density lipoprotein [HDL]), HIV viral load (VL) and CD4 cell counts, hepatitis B and C virus monitoring, were conducted at baseline assessment and at the 48 week follow-up. Resistance tests were performed in ART-naïve patients at baseline and in ART-experienced patients with virologic failure [15]. Dual-energy X-ray absorptiometry (DXA) was used to assess bone mineral density (BMD) in the right and left hips (neck, trochanter, and inside) and lumbar spine (L1–L4) at baseline and 48 weeks after fixed-dose BIC/FTC/TAF initiation. Retrospective laboratory data, including routine blood tests, hepatic and renal functions, renal biomarkers, serum lipid panel, viral load, and CD4 cell counts at baseline and 48 weeks after receiving fixed-dose BIC/FTC/TAF, were abstracted from the electronic medical records, and DXA at baseline and 48 weeks after receiving fixed-dose BIC/FTC/TAF were also recorded for further study. The reasons of patients for switching to fixed-dose BIC/FTC/TAF were extracted from their electronic medical records. Outcomes The primary outcome of this study was to evaluate the HIV viral load below the LLOD among patients switching to fixed-dose BIC/FTC/TAF or ART-naïve patients receiving BIC/FTC/TAF for 48 weeks. The secondary outcome was to assess changes in blood biochemical parameters, including hepatic and renal functions, renal biomarkers, serum lipid panels and bone mineral density 48 weeks after receiving a fixed dose of BIC/FTC/TAF. Statistical analysis Baseline demographic, clinical, and laboratory data, reason for switching to fixed-dose BIC/FTC/TAF, and virologic response which were abstracted from electrical medical records were described in detail. Continuous variables with normal distribution were expressed as mean ± standard deviation (SD) while those with skewed distribution were displayed as median (interquartile range [IQR]), and categorical variables were presented as percentages. Changes in blood biochemical tests including serum lipid panels and bone mineral density at baseline and 48 weeks of follow-up are presented in column charts. A normal control group was included in this study, and an independent sample t-test was also performed for blood biochemical tests including serum lipid panels and bone mineral density between normal controls and study participants at baseline. A paired sample t-test was conducted for blood biochemical tests, bone mineral density values, and serum lipid panels at baseline and 48 weeks of follow-up, while the χ2 test was used to calculate the prevalence of measurement data. SPSS (version 22.0; SPSS Institute, Chicago IL, USA) was used for statistical analysis, and p value less than 0.05 was considered significant in this study. Results Baseline characteristics From April 2023 to April 2024, 314 patients aged > 50 years living with HIV were recruited for this study, including 35 ART-naïve and 279 ART-experienced patients. Among the ART-naive patients, the average age was 57 years (IQR: 54–61 years), and the median CD4 cell count was 317.5 cells/µL (IQR: 131.75–608.50 cells/µL), while among ART-experienced patients, the average age was 56 years (IQR: 53–61 years), and the median CD4 cell count was 579.5 cells/µL (IQR: 392.25–814.75 cells/µL). An HIV viral load above the LLOD was found in 16 patients. In ART-experienced patients, the ART components before switching to fixed-dose BIC/FTC/TAF are presented in Table 1, among which TAF/FTC/EVG/c were the most common components among patients who were switching (68.46%).Table 1Baseline clinical and laboratory characteristicsCharacteristicsNormal ControlTotal patientsART-experienced patientsART-naive patientsAge, years, M (IQR)55(52, 60)56(53, 61)56(53, 61)57(54, 61)Male, n (%)17(85.00)281(91.08)254(67.02)27(77.14)Baseline CD4 T cells, cells/uL, M (IQR)-563.00(350.00, 805.00)579.50(392.25, 814.75)317.50(131.75, 608.50)Baseline viral load VL < 48 copies/mL, n (%)-263(83.76)263(94.27)0(0.00) VL > 48 copies/mL, n (%)-51 (16.24)16(5.73)35(100)Baseline laboratory test TG mmol/L, mean±SD2.25±0.172.32±1.982.31±2.022.39±1.15 TC mmol/L, mean±SD4.29±0.694.79±1.034.83±1.024.41±1.06 LDL mmol/L, mean±SD2.72±0.212.91±0.802.94±0.792.69±0.82 HDL mmol/L, mean±SD1.06±0.091.09±0.291.09±0.291.03±0.27 ALT U/L, mean±SD25.80±9.1328.15±21.7128.62±22.3724.33±15.13 AST U/L, mean±SD24.05±6.6423.84±12.7824.15±13.2021.36±8.39 T-BIL μmol/L, mean±SD13.43±2.9311.38±4.9811.43±4.8311.00±6.11 D-BIL μmol/L, mean±SD6.98±2.163.63±2.223.66±2.233.39±2.18 eGFR mL/min/1.73 m2, mean±SD100.22±6.2990.19±15.3790.42±15.3788.29±14.94 Cr μmol/L, mean±SD86.62±7.6381.25±19.2781.25±18.8879.89±22.41 PRO mg/dL, M (IQR)6.70(5.70, 7.55)15.20 (8.60, 24.20)15.10 (8.50, 23.18)15.90 (7.15, 38.20) ɑ1 MG mg/L, M (IQR)3.50(2.43, 4.25)14.35 (0.00,38.23)14.80 (0.00,39.05)5.90(0.00,33.70) MAU mg/L, M (IQR)14.00(12.03, 18.23)19.00(10.00, 41.00)19.00(11.00, 42.00)20.00(4.50, 36.50) β2 MG mg/L, M (IQR)0.25(0.10, 0.40)0.79(0.36, 1.66)0.78 (0.34, 1.76)0.82 (0.43, 1.18) Cys-C mg/L, M (IQR)1.78 (1.07, 1.28)1.15 (1.00, 1.39)1.14(0.99, 1.36)1.52(1.12, 1.62)Previous ART Components TAF/FTC/EVG/c, n (%)--191(68.46)- ABC+3TC, n (%)--4 (1.43)- TDF+3TC, n (%)--78 (27.96)- AZT+3TC, n (%)--6 (2.15)- EFV, n (%)--72 (25.80)- DTG, n (%)--3 (1.08)- LPV/r, n (%)--10 (3.58)- NVP, n (%)--3 (1.08)-Receiving lipid-lowing drug, n (%)-63(20.06)63 (22.58)-Note: M (IQR): median (interquartile range); SD: standard deviation; VL: viral load; TG: triglyceride; TC: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; ALT: alanine transaminase; AST: aspartate transaminase; T-BIL: total Bilirubin; D-BIL: direct Bilirubin; eGFR: estimated glomerular filtration rate; Cr: creatinine; MAU: microlbunminuria; β2 MG: β2-microglobulin; ɑ1 MG: ɑ1-microglobulin; Cys-C: cystatin C; PRO: proteinuria; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir Alafenamide; FTC: Emtricitabine; EVG/c: Elvitegravir/cobicistat; ABC: abacavir; AZT: Zidovudine; 3TC: lamivudine; EFV: efavirenz; DTG: dolutegravir; LPV/r: lopinavir/ritonavir; NVP: nevirapline; ART: antiretrovival therapy Table 1Baseline clinical and laboratory characteristicsCharacteristicsNormal ControlTotal patientsART-experienced patientsART-naive patientsAge, years, M (IQR)55(52, 60)56(53, 61)56(53, 61)57(54, 61)Male, n (%)17(85.00)281(91.08)254(67.02)27(77.14)Baseline CD4 T cells, cells/uL, M (IQR)-563.00(350.00, 805.00)579.50(392.25, 814.75)317.50(131.75, 608.50)Baseline viral load VL < 48 copies/mL, n (%)-263(83.76)263(94.27)0(0.00) VL > 48 copies/mL, n (%)-51 (16.24)16(5.73)35(100)Baseline laboratory test TG mmol/L, mean±SD2.25±0.172.32±1.982.31±2.022.39±1.15 TC mmol/L, mean±SD4.29±0.694.79±1.034.83±1.024.41±1.06 LDL mmol/L, mean±SD2.72±0.212.91±0.802.94±0.792.69±0.82 HDL mmol/L, mean±SD1.06±0.091.09±0.291.09±0.291.03±0.27 ALT U/L, mean±SD25.80±9.1328.15±21.7128.62±22.3724.33±15.13 AST U/L, mean±SD24.05±6.6423.84±12.7824.15±13.2021.36±8.39 T-BIL μmol/L, mean±SD13.43±2.9311.38±4.9811.43±4.8311.00±6.11 D-BIL μmol/L, mean±SD6.98±2.163.63±2.223.66±2.233.39±2.18 eGFR mL/min/1.73 m2, mean±SD100.22±6.2990.19±15.3790.42±15.3788.29±14.94 Cr μmol/L, mean±SD86.62±7.6381.25±19.2781.25±18.8879.89±22.41 PRO mg/dL, M (IQR)6.70(5.70, 7.55)15.20 (8.60, 24.20)15.10 (8.50, 23.18)15.90 (7.15, 38.20) ɑ1 MG mg/L, M (IQR)3.50(2.43, 4.25)14.35 (0.00,38.23)14.80 (0.00,39.05)5.90(0.00,33.70) MAU mg/L, M (IQR)14.00(12.03, 18.23)19.00(10.00, 41.00)19.00(11.00, 42.00)20.00(4.50, 36.50) β2 MG mg/L, M (IQR)0.25(0.10, 0.40)0.79(0.36, 1.66)0.78 (0.34, 1.76)0.82 (0.43, 1.18) Cys-C mg/L, M (IQR)1.78 (1.07, 1.28)1.15 (1.00, 1.39)1.14(0.99, 1.36)1.52(1.12, 1.62)Previous ART Components TAF/FTC/EVG/c, n (%)--191(68.46)- ABC+3TC, n (%)--4 (1.43)- TDF+3TC, n (%)--78 (27.96)- AZT+3TC, n (%)--6 (2.15)- EFV, n (%)--72 (25.80)- DTG, n (%)--3 (1.08)- LPV/r, n (%)--10 (3.58)- NVP, n (%)--3 (1.08)-Receiving lipid-lowing drug, n (%)-63(20.06)63 (22.58)-Note: M (IQR): median (interquartile range); SD: standard deviation; VL: viral load; TG: triglyceride; TC: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; ALT: alanine transaminase; AST: aspartate transaminase; T-BIL: total Bilirubin; D-BIL: direct Bilirubin; eGFR: estimated glomerular filtration rate; Cr: creatinine; MAU: microlbunminuria; β2 MG: β2-microglobulin; ɑ1 MG: ɑ1-microglobulin; Cys-C: cystatin C; PRO: proteinuria; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir Alafenamide; FTC: Emtricitabine; EVG/c: Elvitegravir/cobicistat; ABC: abacavir; AZT: Zidovudine; 3TC: lamivudine; EFV: efavirenz; DTG: dolutegravir; LPV/r: lopinavir/ritonavir; NVP: nevirapline; ART: antiretrovival therapy Baseline clinical and laboratory characteristics Note: M (IQR): median (interquartile range); SD: standard deviation; VL: viral load; TG: triglyceride; TC: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; ALT: alanine transaminase; AST: aspartate transaminase; T-BIL: total Bilirubin; D-BIL: direct Bilirubin; eGFR: estimated glomerular filtration rate; Cr: creatinine; MAU: microlbunminuria; β2 MG: β2-microglobulin; ɑ1 MG: ɑ1-microglobulin; Cys-C: cystatin C; PRO: proteinuria; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir Alafenamide; FTC: Emtricitabine; EVG/c: Elvitegravir/cobicistat; ABC: abacavir; AZT: Zidovudine; 3TC: lamivudine; EFV: efavirenz; DTG: dolutegravir; LPV/r: lopinavir/ritonavir; NVP: nevirapline; ART: antiretrovival therapy The baseline resistance test indicated that no resistance mutations against NRTIs or INSTIs were found among ART-naïve patients. Resistance tests were also conducted in ART-experienced patients with viral failure, and M184V mutations without K65R or INSTI resistance mutations were found in five patients. Among ART-experienced patients, 63 (22.58%) were receiving lipid-lowering drugs, including fenofibrate and statins, due to coronary arteriosclerosis. Baseline clinical features and biochemical, immune, and virologic tests among ART-naïve and -experienced patients and ART components among ART-experienced patients are described in detail in Table 1. Reasons for switching to fixed-dose BIC/FTC/TAF among ART-experienced older patients living with HIV Among ART-experienced older patients switching to fixed-dose BIC/FTC/TAF, simplifying the regimen (254 cases, 91.04%) was the most common reason, followed by declining to taking ART with food (191 cases, 68.46%), low-level viremia (11 cases, 3.94%), renal dysfunction (9 cases, 3.23%), osteoporosis or osteopenia (6 cases, 2.15%), virologic failure (5 cases, 1.79%), liver dysfunction (3 cases, 1.08%), and central nervous system side effects (2 cases, 0.72%) (Table S1). Efficacy of initiating or switching to fixed-dose BIC/FTC/TAF among older patients living with HIV Among ART-naïve or ART-experienced patients receiving fixed-dose BIC/FTC/TAF, the HIV viral load was followed up at 48 weeks, and the results were below the LLOD at follow-up. Among ART-experienced patients with baseline viral load above the LLOD, including 11 patients with LLV and 5 patients with virologic failure, a resistance test was conducted. Patients with virologic failure and with M184V resistance mutations without K65R or INSTI mutation sites were identified. The new regimen, fixed-dose BIC/FTC/TAF, was re-established among patients with LLV and virologic failure, and the HIV virus was inhibited completely at the 48-week follow-ups, indicating efficient antiretroviral potency and viral load below the LLOD at follow-up. Improvement of BMD after 48 weeks among older patients with HIV initiating or switching to fixed-dose BIC/FTC/TAF BMD values in normal control patients and patients living with HIV prior to initiating of fixed-dose BIC/FTC/TAF (baseline) was also compared, and the results indicated that BMD in patients living with HIV decreased significantly (p < 0.05), including in the lumbar spine and left or right hip joint (Figure S1 and Table S2), which indicated that loss of bone density was prone to occur among patients living with HIV due to the HIV infection itself and the effects of some ART medications, including tenofovir disoproxil fumarate. A DXA scan was conducted in the lumbar spine (L1, L2, L3 and L4) and left or right hip joint (neck, trochanter and inside) at baseline and after 48 weeks of initiation or switching to fixed-dose BIC/FTC/TAF, and the change of absolute value of BMD was compared. Results were as follows: 0.8876 ± 0.1193 vs. 0.9321 ± 0.1071 g/cm2 in L1 (p = 0.030), 0.9260 ± 0.1327 vs. 0.9758 ± 0.1208 g/cm2 in L2 (p = 0.029), 0.9559 ± 0.1386 vs. 1.0139 ± 0.1355 g/cm2 in L3 (p = 0.018), and 0.9411 ± 0.1486 vs. 1.0250 ± 0.1709 g/cm2 in L4 (p = 0.003). The BMD values in the left or right hip joint (neck, trochanter, and inside) improved after 48 weeks of initiation with or switching to fixed-dose BIC/FTC/TAF, although the change was not statistically significant. The absolute values of BMD at baseline and 48-week follow up, with or without switching to BIC/FTC/TAF, and a comparison analysis are presented in detail in Fig. 1 and Table S3.Fig. 1The change of BMD 48-week after switching to TAF/FTC/BIC note: BMD, bone mineral density; (L), left; (R), right; L1, lumbar 1; L2, lumbar 2 The change of BMD 48-week after switching to TAF/FTC/BIC note: BMD, bone mineral density; (L), left; (R), right; L1, lumbar 1; L2, lumbar 2 Evaluation of biochemical results 48 weeks after initiation of fixed-dose BIC/FTC/TAF The hepatic and renal functions and renal biomarkers between normal controls and patients living with HIV prior to initiation of fixed-dose BIC/FTC/TAF (baseline) were compared, and the results indicated that more patients living with HIV had hepatic and renal dysfunction than normal controls (p < 0.001) (Table S4). Hepatic function, including ALT, AST, T-BIL, and D-BIL levels, was also evaluated 48 weeks after receiving fixed-dose BIC/FTC/TAF, and the results indicated that hepatic function improved significantly after initiation or switching to BIC/FTC/TAF (p < 0.001). (Table 2)Table 2The change of hepatic and renal functions after 48-weeks switching to B/F/TAFCharacteristicsBaseline48-weeks follow upP valueHepatic function ALT > 40 U/L, n (%)47(14.97)24(7.64)P < 0.001 AST > 40 U/L, n (%)17(5.41)11(3.50)P < 0.001 TBIL > 20 μmol/L, n (%)18(5.73)16(5.10)P < 0.001Renal function eGFR < 90 mL/min/1.73 m2, n (%)137(43.63)177(56.37)P < 0.001 Cr > 97 μmol/L, n (%)45(14.33)74(23.57)P < 0.001Renal biomarkers* PRO mg/dL, M (IQR)15.20(8.60, 24.20)10.40(5.30, 19.70)0.215 ɑ1 MG mg/L, M(IQR)14.35(0.00, 38.23)5.50(0.00, 28.75)0.067 MAU mg/L, M (IQR)19.00(10.00, 41.00)19.00(9.00, 42.00)0.369 β2 MG mg/L, M (IQR)0.79(0.36, 1.66)0.45(0.25, 1.28)0.931 Cys-C mg/L, M (IQR)1.15(1.00, 1.39)1.21(1.02, 1.50)0.236Note: *the data of renal biomarkers was analyzed using M (IQR) due to skew distribution. ALT: alanine transaminase; AST: aspartate transaminase; T-BIL: total Bilirubin; eGFR: estimated glomerular filtration rate; Cr: creatinine; MAU: microlbunminuria; β2 MG: β2-microglobulin; ɑ1 MG: ɑ1-microglobulin; Cys-C: cystatin C; PRO: proteinuria; B/F/TAF: Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide; M(IQR): median (interquartile range) Table 2The change of hepatic and renal functions after 48-weeks switching to B/F/TAFCharacteristicsBaseline48-weeks follow upP valueHepatic function ALT > 40 U/L, n (%)47(14.97)24(7.64)P < 0.001 AST > 40 U/L, n (%)17(5.41)11(3.50)P < 0.001 TBIL > 20 μmol/L, n (%)18(5.73)16(5.10)P < 0.001Renal function eGFR < 90 mL/min/1.73 m2, n (%)137(43.63)177(56.37)P < 0.001 Cr > 97 μmol/L, n (%)45(14.33)74(23.57)P < 0.001Renal biomarkers* PRO mg/dL, M (IQR)15.20(8.60, 24.20)10.40(5.30, 19.70)0.215 ɑ1 MG mg/L, M(IQR)14.35(0.00, 38.23)5.50(0.00, 28.75)0.067 MAU mg/L, M (IQR)19.00(10.00, 41.00)19.00(9.00, 42.00)0.369 β2 MG mg/L, M (IQR)0.79(0.36, 1.66)0.45(0.25, 1.28)0.931 Cys-C mg/L, M (IQR)1.15(1.00, 1.39)1.21(1.02, 1.50)0.236Note: *the data of renal biomarkers was analyzed using M (IQR) due to skew distribution. ALT: alanine transaminase; AST: aspartate transaminase; T-BIL: total Bilirubin; eGFR: estimated glomerular filtration rate; Cr: creatinine; MAU: microlbunminuria; β2 MG: β2-microglobulin; ɑ1 MG: ɑ1-microglobulin; Cys-C: cystatin C; PRO: proteinuria; B/F/TAF: Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide; M(IQR): median (interquartile range) The change of hepatic and renal functions after 48-weeks switching to B/F/TAF Note: *the data of renal biomarkers was analyzed using M (IQR) due to skew distribution. ALT: alanine transaminase; AST: aspartate transaminase; T-BIL: total Bilirubin; eGFR: estimated glomerular filtration rate; Cr: creatinine; MAU: microlbunminuria; β2 MG: β2-microglobulin; ɑ1 MG: ɑ1-microglobulin; Cys-C: cystatin C; PRO: proteinuria; B/F/TAF: Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide; M(IQR): median (interquartile range) Compared with the baseline results, eGFR reduced significantly while serum creatinine significantly increased 48 weeks after the initiation of or switching to fixed-dose BIC/FTC/TAF (p < 0.001). (Table 2) A comparison of renal biomarkers between normal control and patients living with HIV prior to initiation of fixed-dose BIC/FTC/TAF (baseline) was conducted and results indicated that proteinuria, ɑ1-microglobulin, and β2-microglobulin increased significantly (p < 0.001) while microalbuminuria and cystatin C exhibited generally improved (Table S4). Among these patients, a comparison of renal biomarkers between baseline and 48 weeks of follow-up indicated that renal biomarkers, including proteinuria, ɑ1-microglobulin, microalbuminuria, and β2-microglobulin, were reduced; thus, renal biomarkers improved after 48 weeks of fixed-dose BIC/FTC/TAF treatment, although the difference was not statistically significant. (Table 2) The serum lipid panel in normal control patients and ART-naïve patients living with HIV were also compared, and results were not significantly different. (p > 0.05) (Figure S2 and Table S5). Among ART-naive patients initiated with fixed-dose BIC/FTC/TAF, a comparison of lipid panels at baseline and at the 48-week follow-up yielded the following results: 2.42 ± 1.56 mmol/L vs 2.62 ± 1.58 mmol/L for TG (p = 0.499), 4.42 ± 1.07 mmol/L vs 4.54 ± 0.93 mmol/L for TC (p = 0.516), 2.69 ± 0.83 mmol/L vs 2.60 ± 0.76 mmol/L for LDL (p = 0.417), and 1.04 ± 0.28 mmol/L vs 1.08 ± 0.31 mmol/L for HDL (p = 0.246), indicating that no significant change after 48 weeks of fixed-dose BIC/FTC/TAF treatment in ART-naive older patients living with HIV (Fig. 2 and Table S6).Fig. 2Change of serum lipid panel among HAART-naive patients receiving TAF/FTC/BIC TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein Change of serum lipid panel among HAART-naive patients receiving TAF/FTC/BIC TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein Among ART-experienced patients not receiving lipid-lowering drugs, a comparison of lipid panels at baseline and at 48-week follow-up yielded the following results: 1.86 ± 1.21 mmol/L vs 1.66 ± 1.00 mmol/L for TG (p = 0.013), 4.75 ± 1.02 mmol/L vs 4.68 ± 0.93 mmol/L for TC (p = 0.328), 2.96 ± 0.78 mmol/L vs 2.90 ± 0.78 mmol/L for LDL (p = 0.304), and 1.11 ± 0.30 mmol/L vs 1.15 ± 0.32 mmol/L for HDL (p = 0.018), indicating that TG and HDL profiles significantly improved while TC and LDL levels exhibited improved trends among these patients. (Fig. 3 and Table S7).Fig. 3Change of serum lipid panel 48-week after switching among HAART-experienced patients without receiving lipid-lowering drugs TG, triglyceride; TC, total cholesterol; IDL, low-density lipoprotein; HDL, high-density lipoprotein Change of serum lipid panel 48-week after switching among HAART-experienced patients without receiving lipid-lowering drugs TG, triglyceride; TC, total cholesterol; IDL, low-density lipoprotein; HDL, high-density lipoprotein The comparison of serum lipid panel between normal control and patients receiving EFV/TDF/3TC prior to switching to TAF/FTC/BIC was conducted, and results did not present significant difference except serum TG level (Table S8). Seventy-two ART-experienced patients received TDF/3TC/EFV at baseline and stably switched to fixed-dose BIC/FTC/TAF. A comparison of their lipid profiles at baseline and at 48-week follow up yielded the following results: 1.93 ± 1.23 mmol/L vs 1.63 ± 0.92 mmol/L in TG (p = 0.126), 4.70 ± 0.87 mmo/L vs 4.65 ± 0.96 mmo/L in TC (p = 0.685), 2.89 ± 0.73 mmol/L vs 2.93 ± 0.82 mmol/L in LDL (p = 0.800), and 1.07 ± 0.26 mmol/L vs 1.09 ± 0.28 mmol/L in HDL (p = 0.504), indicating no significant change in lipid profiles were observed after 48 weeks fixed-dose BIC/FTC/TAF treatment in ART-experienced older patients switched from TDF/3TC/EFV (Table S9). In ART-experienced patients, 191 cases (68.46%) received TAF/FTC/EVG/c at baseline and stably switched to fixed-dose BIC/FTC/TAF. Compared with normal control, serum TC and LDL were increased significantly (p < 0.05), while serum TG and HDL were typically increased in patients receiving TAF/FTC/EVG/c at baseline (Table S10). A comparison of their lipid profiles at baseline and at 48-week follow up yielded the following results: 2.45 ± 2.29 mmol/L vs 1.93 ± 1.36 mmol/L for TG (p < 0.001), 4.89 ± 1.08 mmol/L vs 4.76 ± 0.98 mmol/L for TC (p = 0.067), 2.98 ± 0.83 mmol/L vs 2.87 ± 0.83 mmol/L for LDL (p = 0.076), and 1.11 ± 0.30 mmol/L vs 1.17 ± 0.32 mmol/L for HDL (p = 0.003), indicating TG and HDL levels significantly improved while TC and LDL levels exhibited improvements trend among these patients (Table S11). Among ART-experienced patients receiving lipid-lowering drugs, baseline and at 48-week follow-up were presented in Fig. 4 and Table S12.Fig. 4The change of serum lipid panel among patients receiving lipid-lowering drug at 48-week follow-up TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein The change of serum lipid panel among patients receiving lipid-lowering drug at 48-week follow-up TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein Discussion The widespread use of ART [16] has increased survival among HIV-infected populations, resulting in an increase in older individuals living with HIV. Compared with younger patients, older patients suffer from aging-associated comorbidities, including osteopenia or osteoporosis [5], hyperlipidemia [17], and chronic kidney diseases [18], which require additional non-ART treatment. HIV infection influences immune aging [19], resulting in early features of senile diseases related to older age. Older patients living with HIV face more challenges, including more comorbidities and health complications, multidisciplinary diagnosis, and polypharmacy treatment [20]. In this retrospective study, we evaluated the efficacy and safety of treatment with fixed-dose BIC/FTC/TAF in older patients living with HIV and found optimal antiretroviral efficacy, including in patients with the M184V mutation site, and improved outcomes in BMD in the lumbar spine and left or right hip joint, renal biomarkers, and lipid panels 48 weeks after initiating treatment. The major reasons for switching to fixed-dose BIC/FTC/TAF among ART-experienced patients were the simplified regimen, drug-food interactions, and adverse events of the current regimens. Most of the older patients desired simplification due to good economic conditions and medical insurance payment, which was consistent with results of previous studies [21]. EVG/c/TAF/FTC-related drug-food interactions, TDF-related renal dysfunction, reduced BMD, EFV-associated neuropsychiatric symptoms, and LLV or virologic failure were other common reasons for switching. Reportedly [22], resistance mutation sites, including M184V, do not seem to affect the efficacy of BIC/FTC/TAF based on retrospective study of pre-selected study subjects. M184V mutation sites reduced HIV viral fitness in vivo and increased blood drug concentration of some NRTIs, including TAF and TDF [23]. Bictegravir exhibits a high resistance barrier, with no resistance reported in treatment-naïve patients with virologic failure after 144 weeks in the studies GS-US-380–1489/1490 [24]. In this real-world study, virologic failure occurred in five patients receiving TDF+3TC+EFV. M184V mutations were identified; however, no K64R or INSTIs mutation were found and the HIV viral load was completely suppressed after switching to fixed-dose BIC/FTC/TAF at the 48-week follow-up, indicating that fixed-dose BIC/FTC/TAF presented good virologic efficacy among HIV-experienced patients with M184V mutation sites. In this study, we found that 48 weeks after switching to fixed-dose BIC/FTC/TAF serum triglyceride and HDL levels showed significant improvement, while TC and LDL levels displayed other improvement trends in older patients. Rolle et al. [25] reported that lipid panels significantly decreased after 48 weeks among patients aged ≥50 years living with HIV who switched to BIC/FTC/TAF, among whom 54% of patients switched from regimen with boosters, including ritonavir or cobicistat, and 25% who were administered with TDF. Maggiolo et al. [10] also demonstrated significantly lower serum triglycerides and total cholesterol among patients aged > 65 years who were stably switching to BIC/FTC/TAF, among whom 93% of patients switched from a regimen with boosters. These findings are consistent with our results. In this study, 27.96% of patients switched from regimens with TDF and the switch resulted in lipid-lowering effects. Conversely, 25.4% of patients switched from regimens with EFV and 72.04% from regimens with boosters and the switch resulted in lipid-raising effects. We also found that serum triglycerides were significantly reduced 48 weeks after switching to BIC/FTC/TAF, which indicated that BIC/FTC/TAF can be treated as a good alternative regimen among older ART-experienced patients. In this study, among 63 patients received lipid-lowering drugs including fenofibrate and statins owing to cardiovascular disorders, we also found that serum triglycerides reduced significantly and total cholesterol, LDL cholesterol decreased the 48-week follow-up, which should help to stabilize vascular plaques and reduce the risk of coronary atherosclerosis among these older patients. Renal function tests indicated significantly increased serum creatinine and reduced eGFR levels without discontinuation due to renal side effects, whereas renal biomarkers exhibited reduced trends 48 weeks after switching to fixed-dose BIC/FTC/TAF. β2-microglobulin (β2 MG) [26]and ɑ1-microglobulin (ɑ1 MG) [27] are low-molecular-weight proteins that can freely passes through the glomerular filtration barrier and undergo reabsorption. These biomarkers serve as sensitive indicators of early tubular dysfunction. Cystain C (CysC) another glomerular filtration marker [28], offers advantages over traditional metrics as it is unaffected by muscle mass or gender, enabling earlier detection of renal impairment before abnormalities in conventional paremeters become apparent. This biomarker profile aligns with our renal function observations. Reportedly, 48 weeks after fixed-dose combination BIC/FTC/TAF initiation, participant renal marker levels were comparable to baseline levels and did significantly decrease, while the proportion of subjects with eGFR < 90 mL/min/1.73 m2 significantly increased compared to the baseline, which may be related to the ability of integrase inhibitors to inhibit organic cation transporter-2 (OCT-2), thereby suppressing renal tubular excretion of creatinine [29]. Nevertheless, no participants stopped the medication due to renal-related adverse events, suggesting the renal safety of BIC/FTC/TAF. Renal biomarkers have been reported to improve to some degree after switching to fixed-dose BIC/FTC/TAF [29]. These findings are similar to our results, which indicate that BIC/FTC/TAF can improve renal function in older patients. Patients living with HIV often have reduced BMD and osteopenia and osteoporosis were the most common non-AIDS-defining events among the ART-naïve and ART-experienced populations [5], especially in older patients. The causes included traditional risk factors including smoking, alcohol abuse, vitamin D deficiency, chronic HIV infection, and direct ART side effects, including tenofovir-based ARV regimens [30]. A potent ARV regimen with improved BMD outcomes is necessary for older patients living with HIV. A meta-analysis by Tao et al. [31] indicated that, compared with those receiving TDF-containing regimens, patients on TAF-containing regimens presented significantly smaller reductions in BMD in both the hip and spine. Kanda et al. [32] reported that among 118 Japanese patients living with HIV who switched from TDF-containing-to TAF-containing regimens, BMD improved 1-year after switching. In this study, a similar conclusion was made including significantly improved BMD in lumbar spine (L1, L2, L3, and L4) and improvement trends in the left or right hip joint (neck, trochanter, and inside), which indicated that, among older patients living with HIV and osteopenia, osteoporosis, and even fracture, fixed-dose TAF/FTC/BIC may be a good choice for antiretroviral therapy. This study had some limitations. First, this was a single-center study, therefore, the results may lack generalizability and cannot represent a similar conclusion made in other centers. The results should be further validated based on a multicenter, large cohort study. Second, potential bias cannot be ruled owing to the retrospective nature of this observational study. Third, the conclusion of this study was based on a 48-week follow-up period, and should be further assessed based on long-term observations. This real-world study indicated that fixed-dose BIC/FTC/TAF displayed good efficacy among older patients, even in those with the M184V mutation. After receiving BIC/FTC/TAF, BMD in the lumbar spine (L1, L2, L3, and L4) improved significantly, whereas those in the left or right hip joints (neck, trochanter, and inside) showed tended to improve. Renal biomarkers were improved, despite significantly increased serum creatinine and reduced eGFR levels, whereas serum TG and HDL levels significantly improved and TC and LDL exhibited improvements among ART-experienced older patients. Among patients who received lipid-lowering drugs for coronary arteriosclerosis, serum TG levels also significantly improved, which indicated that fixed-dose BIC/FTC/TAF is a good option for older patients living with HIV. Electronic supplementary material Below is the link to the electronic supplementary material. Figure S1: The comparison of BMD between normal control and patients at baseline Note: BMD, bone mineral density; (L), left; (R), right. Figure S1: The comparison of BMD between normal control and patients at baseline Note: BMD, bone mineral density; (L), left; (R), right. Figure S2: The comparison of serum lipid panel between control and HAART-naive patient at baseline TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein. Figure S2: The comparison of serum lipid panel between control and HAART-naive patient at baseline TG, triglyceride; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein. Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5 Supplementary Material 6 Supplementary Material 6 Supplementary Material 7 Supplementary Material 7 Supplementary Material 8 Supplementary Material 8 Supplementary Material 9 Supplementary Material 9 Supplementary Material 10 Supplementary Material 10 Supplementary Material 11 Supplementary Material 11 Supplementary Material 12 Supplementary Material 12 Supplementary Material 13 Supplementary Material 13 Supplementary Material 14 Supplementary Material 14